CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Visiting Nurse Service of New York

Susan Northover, SVP Patient Care Services

How Technological Innovation is Transforming Home and Community-Based Healthcare Delivery

Susan Northover

Susan Northover

While people often associate healthcare technology with the state-of-the-art scanning, life-support and surgical equipment found in modern medical centers, some of the most interesting health-related innovations are now happening in the home care arena, as the healthcare industry focuses increasingly on helping people maintain their health and manage their chronic conditions in a community setting—thereby reducing the need for costly hospitalizations.


“As the United States’ largest not-for-profit home and community-based healthcare provider, VNSNY uses technological innovation to advance a number of important goals”


As the United States’ largest not-for-profit home and community-based healthcare provider, the Visiting Nurse Service of New York (VNSNY) uses technological innovation to advance a number of important goals. We rely on innovation to improve our care delivery while also reducing costs; to gain a competitive advantage in the home care marketplace; and to maintain our role as a healthcare leader and change agent. To support these efforts, we’re continually looking for ways we can leverage technology to help our staff perform their work more effectively, enhance the services we provide to our patients and members, and improve our ability to meet our customers’ and our own organization’s needs.


How We Select New Products or Services


While innovation has always been a big part of VNSNY, we recently redesigned our innovation strategy and approach and are now working to implement that redesign. To facilitate our implementation of innovative technologies, VNSNY employs a codified, step-by-step process for the selection and adoption of new products and services. This internal innovation process is overseen by our Executive VP for Strategy and, in the future, a VP of Innovation, and is supported by VNSNY’s Performance and Innovation Department.


The selection process begins with a “search” phase, which involves our innovation leadership casting a wide net to surface new technologies, drawing on academic resources such as journal databases and white papers, conferences and other technology events, online searches, and ideas generated through our leadership and employee networks, industry partners, and other subject matter experts. When a promising product or service has been identified, members of our team will meet with the vendor to gain a better understanding of the product, including how it’s used, its price parameters and overall value proposition, and the product’s prior results.


 


Following this step, if we are still interested in pursuing the product or service, we’ll meet with an Innovation Panel, made up of VNSNY leadership and subject matter experts from the relevant VNSNY business units, to review the technology and determine if we want to move ahead—and if so, then how and where the product could best be piloted within our organization. This review will include having the vendor conduct a demonstration for the Innovation Panel. The review process, which varies somewhat by product and vendor, is typically supplemented by additional input from other key decision makers. The aim of this broad outreach is to avoid a siloed approach by soliciting perspectives from across the organization, so that we understand all the cross-functional implications of the product.


How We Design Pilots


If the product is green-lighted, we’ll then take the next step, and design and implement a pilot project to test it in the field. VNSNY’s piloting process is central to our innovation strategy. This process begins with a careful delineation of the product’s intended benefits, including problems or challenges that need to be addressed as well as the pilot’s desired outcomes, such as improvements in clinical efficacy, operational efficiency, and cost reduction. Next, the pilot’s target test group is identified and the pilot itself is designed in accordance with a number of key parameters— ensuring, among other things, that the sample size is large enough to validate the pilot’s results, and that the right controls and metrics are in place.


After the pilot design is completed, we identify and train the staff who will be conducting the pilot. Following the pilot’s launch, we continue to work closely with the vendor to reassess and refine the pilot’s design as needed. Depending on the product, a pilot can last anywhere from one month to a year. Once the pilot is concluded, we carefully assess its outcomes and compare these against the project’s goals. This information is presented to a second expert Innovation Panel, which reviews the pilot results, including clinical and quality outcomes and cost savings. This panel will then decide whether to move forward with either an expanded pilot, an enterprise-wide rollout of the product or service—or, if the results merit, an investment opportunity.


Examples of Products and Services Being Piloted


In practice, we’ve applied or plan to apply this approach to a wide range of innovative products and services, including telehealth systems, risk stratification tools, in-home care management devices, recruitment tools, and clinical technologies aimed at enhancing the effectiveness of our nurses and therapists. While each product or service is unique, they share one important element: All of the innovations we select for piloting have the potential to improve how VNSNY serves our patients, clients and plan members, by enhancing our ability to provide quality, coordinated care management in a more consistent and cost-effective way. Even better, these multiple innovations often have a synergistic impact over time. Given today’s rapidly evolving world of home healthcare, technological innovation is more than a strategy at VNSNY: It’s our ticket to the future.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/how-technological-innovation-is-transforming-home-and-communitybased-healthcare-delivery-nwid-445.html